2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow entrectinib: new trials by email Literature Review of entrectinib trials Research Report on entrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma PAC-1, Entrectinib - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Arkadiusz Z. Dudek, MD | 6 | 2021-01-11 | 2023-11-22 |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Capmatinib, Ceritinib, Entrectinib - ALK Fusion Protein Expression, BRAF wt Allele | Phase 2 | Terminated | University of California, San Francisco | 1 | 2015-03-26 | 2020-01-27 |
Melanoma (1) · Noonan Syndrome 6 (1) · Uveal Melanoma (1)
Arkadiusz Z. Dudek, MD (1) · University of California, San Francisco (1)
United States (2)
Adil Daud (1) · Arkadiusz Dudek, MD, PhD (1)